STEMI patients treated by primary PCI with low apelin levels depicted an unfavorable clinical profile (older age, higher LDL, hs-CRP, peak CK-MB and TNI values, and more obstructed vessels), and those patients also had higher incidences of MACE within the following 12-month, which is in accordance with the current evidence on the cardioprotective role of apelin.16 It is well known that apelin decreases in patients with severe left ventricular impairment10 and chronic heart failure,7 factors that highly influence the survival of STEMI patients. The gene discussed is APLN; the disease is congestive heart failure.